In order to initiate the use of a multileaf collimator (MLC) in the clinic, a set of technical procedures needs to be available sufficient to create MLC leaf settings and to deliver an accurate dose of radiation through the MLC-shaped field. Dosimetry data for clinical use of the MLC were measured. Dosimetric characteristics included central axis percent depth dose, output factors, and penumbra. In this paper, it has been concluded that a dose control monitor unit calculation procedure that has been applied to the use of conventional secondary field-shaping blocks can be applied to the multileaf collimator dosimetry. The multileaf collimator penumbra (20% to 80%) is only slightly wider (1-3 mm) than the penumbra of the conventional collimator jaws. Beam's-eye-view comparisons made between the isodose curves in fields shaped by conventional Cerrobend blocks and isodose curves in fields shaped by the multileaf collimator demonstrated that the 50% isodose line at 10-cm depth exhibited the discrete steps of the multileaf collimator leaves, but that the 90% and 10% isodose curves of the multileaf were close to those shaped by Cerrobend blocks.

Background: This study evaluated the dosimetric impact of various treatment techniques as well as collimator leaf width (2.5 vs 5 mm) for three groups of tumors -spine tumors, brain tumors abutting the brainstem, and liver tumors. These lesions often present challenges in maximizing dose to target volumes without exceeding critical organ tolerance. Specifically, this study evaluated the dosimetric benefits of various techniques and collimator leaf sizes as a function of lesion size and shape.

The purpose of this study was to perform comprehensive measurements and testing of a Novalis Tx linear accelerator, and to develop technical guidelines for commissioning from the time of acceptance testing to the first clinical treatment. The Novalis Tx (NTX) linear accelerator is equipped with, among other features, a high‐definition MLC (HD120 MLC) with 2.5 mm central leaves, a 6D robotic couch, an optical guidance positioning system, as well as X‐ray‐based image guidance tools to provide high accuracy radiation delivery for stereotactic radiosurgery and stereotactic body radiation therapy procedures. We have performed extensive tests for each of the components, and analyzed the clinical data collected in our clinic. We present technical guidelines in this report focusing on methods for: (1) efficient and accurate beam data collection for commissioning treatment planning systems, including small field output measurements conducted using a wide range of detectors; (2) commissioning tests for the HD120 MLC; (3) data collection for the baseline characteristics of the on‐board imager (OBI) and ExacTrac X‐ray (ETX) image guidance systems in conjunction with the 6D robotic couch; and (4) end‐to‐end testing of the entire clinical process. Established from our clinical experience thus far, recommendations are provided for accurate and efficient use of the OBI and ETX localization systems for intra‐ and extracranial treatment sites. Four results are presented. (1) Basic beam data measurements: Our measurements confirmed the necessity of using small detectors for small fields. Total scatter factors varied significantly (30% to approximately 62%) for small field measurements among detectors. Unshielded stereotactic field diode (SFD) overestimated dose by ~ 2% for large field sizes. Ion chambers with active diameters of 6 mm suffered from significant volume averaging. The sharpest profile penumbra was observed for the SFD because of its small active diameter (0.6 mm). (2) MLC commissioning: Winston Lutz test, light/radiation field congruence, and Picket Fence tests were performed and were within criteria established by the relevant task group reports. The measured mean MLC transmission and dynamic leaf gap of 6 MV SRS beam were 1.17% and 0.36 mm, respectively. (3) Baseline characteristics of OBI and ETX: The isocenter localization errors in the left/right, posterior/anterior, and superior/inferior directions were, respectively, −0.2±0.2 mm, −0.8±0.2 mm, and −0.8±0.4 mm for ETX, and 0.5±0.7 mm, 0.6±0.5 mm, and 0.0±0.5 mm for OBI cone‐beam computed tomography. The registration angular discrepancy was 0.1±0.2°, and the maximum robotic couch error was 0.2°. (4) End‐to‐end tests: The measured isocenter dose differences from the planned values were 0.8% and 0.4%, measured respectively by an ion chamber and film. The gamma pass rate, measured by EBT2 film, was 95% (3% DD and 1 mm DTA). Through a systematic series of quantitative commissioning experiments and end‐to‐end tests and our initial clinical experience, described in this ...

The emerging biological understanding of metastatic cancer and proof-of-concept clinical trials suggest that debulking all gross disease holds great promise for improving patient outcomes. However, ablation of multiple targets with conventional external beam radiotherapy (EBRT) systems is burdensome, which limits investigation and utilization of complete metastatic ablation in the majority of patients with advanced disease. To overcome this logistical hurdle, technical innovation is necessary. Biology-guided radiotherapy (BgRT) is a new EBRT delivery modality combining PET-CT with a 6 MV linear accelerator. The key innovation is continuous response of the linear accelerator to outgoing tumor PET emissions with beamlets of radiotherapy at subsecond latency. This allows the deposited dose to track tumors in real time. Multiple new hardware and algorithmic advances further facilitate this low-latency feedback process. By transforming tumors into their own fiducials after intravenous injection of a radiotracer, BgRT has the potential to enable complete metastatic ablation in a manner efficient for a single patient and scalable to entire populations with metastatic disease. Future trends may further enhance the utility of BgRT in the clinic as this technology dovetails with other innovations in radiotherapy, including novel dose painting and fractionation schemes, radiomics, and new radiotracers.

No abstract